PL3556351T3 - Kompozycja farmaceutyczna do zwiększania poziomów żelaza we krwi, zawierająca żelazo (iii) z polimaltozą i inną substancję czynną, odpowiednią pod względem wchłaniania żelaza, wybraną spośród pentahydratu folinianu wapnia, witaminy c lub połączenia obu - Google Patents
Kompozycja farmaceutyczna do zwiększania poziomów żelaza we krwi, zawierająca żelazo (iii) z polimaltozą i inną substancję czynną, odpowiednią pod względem wchłaniania żelaza, wybraną spośród pentahydratu folinianu wapnia, witaminy c lub połączenia obuInfo
- Publication number
- PL3556351T3 PL3556351T3 PL19386016.0T PL19386016T PL3556351T3 PL 3556351 T3 PL3556351 T3 PL 3556351T3 PL 19386016 T PL19386016 T PL 19386016T PL 3556351 T3 PL3556351 T3 PL 3556351T3
- Authority
- PL
- Poland
- Prior art keywords
- iron
- polymaltose
- vitamin
- blood
- iii
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title 4
- 229910052742 iron Inorganic materials 0.000 title 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 235000008207 calcium folinate Nutrition 0.000 title 1
- 239000011687 calcium folinate Substances 0.000 title 1
- -1 calcium folinate pentahydrate Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20180100160A GR1009597B (el) | 2018-04-16 | 2018-04-16 | Φαρμακευτικο σκευασμα για την ενισχυση των επιπεδων σιδηρου στο αιμα, που περιεχει πολυμαλτοζικο σιδηρο (ιιι) και μια δραστικη ουσια επιλεγμενη απο πενταϋδρικο φυλλινικο ασβεστιο, βιταμινη c ή συνδυασμο των δυο, που ενισχυει την απορροφηση σιδηρου |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3556351T3 true PL3556351T3 (pl) | 2023-11-27 |
Family
ID=66102021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19386016.0T PL3556351T3 (pl) | 2018-04-16 | 2019-03-22 | Kompozycja farmaceutyczna do zwiększania poziomów żelaza we krwi, zawierająca żelazo (iii) z polimaltozą i inną substancję czynną, odpowiednią pod względem wchłaniania żelaza, wybraną spośród pentahydratu folinianu wapnia, witaminy c lub połączenia obu |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3556351B1 (pl) |
| DK (1) | DK3556351T3 (pl) |
| ES (1) | ES2956286T3 (pl) |
| FI (1) | FI3556351T3 (pl) |
| GR (1) | GR1009597B (pl) |
| HR (1) | HRP20231108T1 (pl) |
| HU (1) | HUE063948T2 (pl) |
| LT (1) | LT3556351T (pl) |
| MA (1) | MA49589B1 (pl) |
| PL (1) | PL3556351T3 (pl) |
| PT (1) | PT3556351T (pl) |
| RS (1) | RS64559B1 (pl) |
| SI (1) | SI3556351T1 (pl) |
| SM (1) | SMT202300309T1 (pl) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
| IT1237509B (it) * | 1989-10-31 | 1993-06-08 | Magis Farmaceutici | Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche |
| CN101282735A (zh) * | 2005-10-11 | 2008-10-08 | 拜耳消费者保健股份公司 | 掩蔽金属味道的铁盐和铜盐混合物 |
| EP1790356A1 (de) * | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
| ITTO20120506A1 (it) | 2012-06-12 | 2013-12-13 | Inge Spa | Cappuccio per un flacone atto alla conservazione di sostanze da mantenersi separate fino alla loro applicazione. |
| EP2997968A1 (en) | 2014-09-22 | 2016-03-23 | Ioulia Tseti | Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same |
-
2018
- 2018-04-16 GR GR20180100160A patent/GR1009597B/el active IP Right Grant
-
2019
- 2019-03-22 ES ES19386016T patent/ES2956286T3/es active Active
- 2019-03-22 SI SI201930621T patent/SI3556351T1/sl unknown
- 2019-03-22 HU HUE19386016A patent/HUE063948T2/hu unknown
- 2019-03-22 RS RS20230778A patent/RS64559B1/sr unknown
- 2019-03-22 PL PL19386016.0T patent/PL3556351T3/pl unknown
- 2019-03-22 HR HRP20231108TT patent/HRP20231108T1/hr unknown
- 2019-03-22 FI FIEP19386016.0T patent/FI3556351T3/fi active
- 2019-03-22 LT LTEP19386016.0T patent/LT3556351T/lt unknown
- 2019-03-22 SM SM20230309T patent/SMT202300309T1/it unknown
- 2019-03-22 MA MA49589A patent/MA49589B1/fr unknown
- 2019-03-22 DK DK19386016.0T patent/DK3556351T3/da active
- 2019-03-22 PT PT193860160T patent/PT3556351T/pt unknown
- 2019-03-22 EP EP19386016.0A patent/EP3556351B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202300309T1 (it) | 2023-11-13 |
| LT3556351T (lt) | 2023-09-25 |
| SI3556351T1 (sl) | 2024-02-29 |
| HUE063948T2 (hu) | 2024-02-28 |
| FI3556351T3 (fi) | 2023-10-02 |
| RS64559B1 (sr) | 2023-10-31 |
| MA49589B1 (fr) | 2023-09-27 |
| HRP20231108T1 (hr) | 2023-12-22 |
| MA49589A (fr) | 2020-05-20 |
| EP3556351B1 (en) | 2023-08-09 |
| DK3556351T3 (da) | 2023-09-18 |
| GR1009597B (el) | 2019-09-16 |
| PT3556351T (pt) | 2023-09-12 |
| ES2956286T3 (es) | 2023-12-18 |
| EP3556351A1 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288104B1 (en) | Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| MX2020010607A (es) | Compuestos y metodos para inhibir el transporte de fosfato. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
| CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
| PH12016500433B1 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| WO2015059463A3 (en) | Treatment of beta-catenin related diseases8 | |
| NO20085147L (no) | Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| EP3566702A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE | |
| TR201004464A2 (tr) | Kemik erimesi için formülasyon. | |
| ATE294585T1 (de) | Vorbeugung von kolorektalkrebs | |
| LT3556351T (lt) | Farmacinė kompozicija, skirta padidinti geležies lygį kraujyje, apimanti geležies (iii) polimaltozę ir kitokią veikliąją medžiagą, tinkamą geležies absorbcijai, pasirinktą iš kalcio folinato pentahidrato, vitamino c arba jų abiejų derinio | |
| PH12019502290A1 (en) | Therapeutic agent for blood cancer | |
| PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
| GB2592457B (en) | Bad odor reduction by Mg complex in deodorant emulsion for aerosols, deodorant comprising the same and use of the deodorant | |
| DE60233869D1 (de) | Prävention von epithelzellkarzinom | |
| PH22014000055Y1 (en) | A composition for a vitamin supplement containing calcium, vitamin c and vitamin d3 for better absorption | |
| PL1700597T3 (pl) | Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól |